Crinecerfont: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Crinecerfont. Educational only — not medical advice.
Labeled uses
CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
Source: FDA labeling via NIH DailyMed (set fd3a6fbd…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.